IP Library › Granted Patent US 12,551,482
Granted Patent B2
US 12,551,482 · App. 17/461,616 · Granted Feb 17, 2026

Aurora kinase inhibitors

Inventors: Justin Gabriel Meyerowitz (San Francisco, CA); William Clay Gustafson (San Francisco, CA); William A. Weiss (San Francisco, CA); Nicholas T. Hertz (San Francisco, CA); Kevan M. Shokat (San Francisco, CA)
Assignee: The Regents of the University of California
A61K31/506C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,482
App. No.
17/461,616
Granted
Feb 17, 2026
Kind
B2
Abstract

Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.

Claims (7)

1 . A method of treating a Myc family protein pathway-associated cancer in a patient in need thereof, wherein the Myc family protein pathway-associated cancer is a breast cancer, colon cancer, or brain cancer, said method comprising administering to the patient a therapeutically effective amount of a compound having the formula:

2 . The method of claim 1 , wherein the Myc family protein pathway-associated cancer is a brain cancer.

3 . The method of claim 2 , wherein the brain cancer is MED311 medulloblastoma.

4 . The method of claim 1 , wherein the Myc family protein pathway-associated cancer is a breast cancer.

5 . The method of claim 4 , wherein the breast cancer is SUM143 breast cancer.

6 . The method of claim 1 , wherein the Myc family protein pathway-associated cancer is a colon cancer.

7 . The method of claim 6 , wherein the colon cancer is RKO colon cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2021
From: MEYEROWITZ, JUSTIN GABRIEL; GUSTAFSON, WILLIAM CLAY; WEISS, WILLIAM A.; HERTZ, NICHOLAS T.; SHOKAT, KEVAN M.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 058286/0496 →
Continuity (4)
Division 14948078 · Nov 20, 2015
Continuation PCTUS2014039238 · May 22, 2014
Provisional Application 61826409 · May 22, 2013
Related Publication 20220054489A1 · Feb 24, 2022
References Cited (21)
US 4861760A · Mazuel et al. · 1989 [cited by applicant]
US 4911920A · Jani et al. · 1990 [cited by applicant]
US 5212162A · Missel et al. · 1993 [cited by applicant]
US 5403841A · Lang et al. · 1995 [cited by applicant]
US 8815885B2 · Walter · 2014 [cited by examiner]
US 9382230B2 · Walter · 2016 [cited by examiner]
US 11135222B2 · Meyerowitz et al. · 2021 [cited by applicant]
US 20110237598A1 · Stadtmueller et al. · 2011 [cited by applicant]
US 20110245249A1 · Wasnaire et al. · 2011 [cited by applicant]
US 20110319436A1 · Walter et al. · 2011 [cited by applicant]
US 20120202818A1 · Tao et al. · 2012 [cited by applicant]
US 20140378488A1 · Ding · 2014 [cited by examiner]
EP 2754659A1 · 2014 [cited by applicant]
WO WO2007056221A2 · 2007 [cited by examiner]
WO WO2010031056 · 2010 [cited by applicant]
WO WO2013033862A1 · 2013 [cited by applicant]
Gustafson et al. Oncogene. 2010; 29:1249-1259, Myc proteins as therapeutic targets. (Year: 2010). [cited by examiner]
Gustafson et al. Cancer Cell. Sep. 8, 2014; 26(3): 414-427. doi:10.1016/j.ccr.2014.07.015. “Drugging MYCN through an allosteric transition in Aurora Kinase A”. (Year: 2014). [cited by examiner]
Brockmann et al. Cancer Cell 24, 75-89, Jul. 8, 2013, Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma (Year: 2013). [cited by examiner]
International Search Report mailed on Sep. 12, 2014, for PCT Application No. PCT/US2014/039238, filed May 22, 2014, 4 pages. [cited by applicant]
Written Opinion mailed on Sep. 12, 2014, for PCT Application No. PCT/US2014/039238, filed May 22, 2014, 8 pages. [cited by applicant]